Spots Global Cancer Trial Database for pld
Every month we try and update this database with for pld cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT06161025 | Solid Cancer | R-DXd Gemcitabine Paclitaxel Topotecan PLD | 18 Years - | Daiichi Sankyo | |
| Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02272790 | Ovarian, Fallop... | Adavosertib Paclitaxel Carboplatin Gemcitabine PLD | 18 Years - 130 Years | AstraZeneca | |
| Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer | NCT02431559 | Ovarian Cancer | Durvalumab Pegylated Lipos... Motolimod | 18 Years - | Ludwig Institute for Cancer Research | |
| Reprab Study: PLD + Trabectedin Rechallenge | NCT04887961 | Relapsed Ovaria... | PLD and Trabect... | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) | NCT02580058 | Ovarian Cancer | avelumab PLD | 18 Years - | Pfizer | |
| Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer | NCT03690739 | Recurrent Ovari... | Carboplatin Gemcitabine Bevacizumab PLD Paclitaxel PLD Trabectedin Cisplatin | 18 Years - | AGO Research GmbH | |
| PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma | NCT03387943 | Poorly Differen... | PLD Cisplatin | 18 Years - 70 Years | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | |
| Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD) | NCT03949634 | Early Breast Ca... | PLD CTX Docetaxel Paclitaxel Doxorubicin | 18 Years - 75 Years | Fudan University | |
| Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer | NCT03690739 | Recurrent Ovari... | Carboplatin Gemcitabine Bevacizumab PLD Paclitaxel PLD Trabectedin Cisplatin | 18 Years - | AGO Research GmbH | |
| Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer | NCT03690739 | Recurrent Ovari... | Carboplatin Gemcitabine Bevacizumab PLD Paclitaxel PLD Trabectedin Cisplatin | 18 Years - | AGO Research GmbH | |
| Reprab Study: PLD + Trabectedin Rechallenge | NCT04887961 | Relapsed Ovaria... | PLD and Trabect... | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients | NCT03123770 | Breast Cancer | Pegylated lipos... Cyclophosphamid... Epirubicin Docetaxel | 18 Years - 70 Years | Zhejiang University | |
| Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02272790 | Ovarian, Fallop... | Adavosertib Paclitaxel Carboplatin Gemcitabine PLD | 18 Years - 130 Years | AstraZeneca | |
| A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | NCT03872947 | Solid Tumor Colorectal Canc... Cholangiocarcin... Bladder Cancer Ovarian Cancer Gastric Cancer Palpable Subcut... Renal Cell Carc... Melanoma Epithelial Ovar... Primary Periton... Fallopian Tube ... | TRK-950 TRK-950 TRK-950 Irinotecan Leucovorin 5-FU Gemcitabine Cisplatin Carboplatin Ramucirumab Paclitaxel Nivolumab Pembrolizumab Imiquimod Cream Bevacizumab PLD | 18 Years - | Toray Industries, Inc | |
| Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients | NCT03123770 | Breast Cancer | Pegylated lipos... Cyclophosphamid... Epirubicin Docetaxel | 18 Years - 70 Years | Zhejiang University | |
| A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT06161025 | Solid Cancer | R-DXd Gemcitabine Paclitaxel Topotecan PLD | 18 Years - | Daiichi Sankyo | |
| A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) | NCT02580058 | Ovarian Cancer | avelumab PLD | 18 Years - | Pfizer | |
| A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD | NCT05281328 | Polycystic Live... | CAM2029 Placebo | 18 Years - | Camurus AB | |
| Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients | NCT03419494 | Adult Acute Lym... | PLD DNR | 14 Years - 60 Years | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | |
| Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer | NCT02431559 | Ovarian Cancer | Durvalumab Pegylated Lipos... Motolimod | 18 Years - | Ludwig Institute for Cancer Research | |
| Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer | NCT01837251 | Recurrent Plati... | Carboplatin PLD Bevacizumab | 18 Years - | AGO Research GmbH | |
| PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma | NCT03387943 | Poorly Differen... | PLD Cisplatin | 18 Years - 70 Years | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
